Luca Marzano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luca Marzano has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Adam S. Darwich
Division of Health Informatics and Logistics, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of Technology, Stockholm, Sweden
7 shared publicationsSebastiaan Meijer
Division of Health Informatics and Logistics, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of Technology, Stockholm, Sweden
7 shared publicationsAsaf Dan
Dept. of Oncology-Pathology, Karolinska Institutet and the Thoracic Oncology Center, Karolinska University hospital, Stockholm, Sweden
5 shared publicationsJayanth Raghothama
Division of Health Informatics and Logistics, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of Technology, Stockholm, Sweden
5 shared publicationsLuigi De Petris
Dept. of Oncology-Pathology, Karolinska Institutet and the Thoracic Oncology Center, Karolinska University hospital, Stockholm, Sweden
5 shared publications- Adam S. Darwich
KTH Royal Institute of Technology
4 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e84042
Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach
Background: Small cell lung cancer (SCLC) is a challenging disease to treat due to rapid progression, development of chemoresistance, and discrepancies in outcomes between real-world data and clinical trials. There is a lack of comprehensive analyses in other studies with regard to intermediate events and the treatment process, such as treatment decisions, progression of disease, and the occurrence of adverse events (AEs) over time. Objective: The aim of this study was to apply advanced statistical methods to a longitudinal SCLC dataset in order to identify factors of importance for the risk of AEs and for survival. Methods: Treatment pathways of 421 patients with SCLC collected from Karolinska University Hospital, located in Stockholm, Sweden, between 2016 and 2022, were analyzed with data-driven modeling. The analysis focused on the impact of dose adjustment on AEs, including neutropenia, by estimating odds ratios (ORs) using Bayesian mixed effects modeling. Covariates’ effects on Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration and early discontinuation of chemotherapy with cause-specific hazard ratios (csHR) were explored using competitive risk models. This approach was applied to patient cohorts receiving combinatorial first-line platinum/etoposide and second-line platinum/etoposide or platinum/irinotecan. Results: At the end of the first-line treatment, most patients exhibited tumor regression (n=167). Patients with neutropenia had longer overall survival (hazard ratio 0.70, 95% CI 0.53-0.92). Higher etoposide dose levels were associated with subsequent occurrences of AEs (OR 5.97, 95% CI 1.41-30.5) and neutropenia (OR 3.55, 95% CI 1.03-13.3). Dose adjustment did not affect overall survival if the patient completed the 4-dose regimen treatment. With regard to second-line therapy, fewer patients completed 4 treatment cycles, and the most common reason for early discontinuation was tumor progression (n=72, 58%). Male patients (n=118) experienced fewer AEs and better first-line treatment response compared to females (csHR 0.51, 95% CI 0.25-0.90). High-risk patients (defined as ECOG PS 2‐3 or age >75 years) with early discontinuation of therapy had survival outcomes similar to those who did not receive any therapy. Conclusions: Our results indicate that first-line therapies may benefit from more individualized dosing strategies. It would also be beneficial to assess the risk-benefit of treating specific subgroups, including patients receiving second-line therapy. Real-world data proved beneficial for studying therapy response and risk-benefit of treating patient groups that are underrepresented in clinical trials.
- 10 April 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e84042
Open AccessReal-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach
Background: Small cell lung cancer (SCLC) is a challenging disease to treat due to rapid progression, development of chemoresistance, and discrepancies in outcomes between real-world data and clinical trials. There is a lack of comprehensive analyses in other studies with regard to intermediate events and the treatment process, such as treatment decisions, progression of disease, and the occurrence of adverse events (AEs) over time. Objective: The aim of this study was to apply advanced statistical methods to a longitudinal SCLC dataset in order to identify factors of importance for the risk of AEs and for survival. Methods: Treatment pathways of 421 patients with SCLC collected from Karolinska University Hospital, located in Stockholm, Sweden, between 2016 and 2022, were analyzed with data-driven modeling. The analysis focused on the impact of dose adjustment on AEs, including neutropenia, by estimating odds ratios (ORs) using Bayesian mixed effects modeling. Covariates’ effects on Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration and early discontinuation of chemotherapy with cause-specific hazard ratios (csHR) were explored using competitive risk models. This approach was applied to patient cohorts receiving combinatorial first-line platinum/etoposide and second-line platinum/etoposide or platinum/irinotecan. Results: At the end of the first-line treatment, most patients exhibited tumor regression (n=167). Patients with neutropenia had longer overall survival (hazard ratio 0.70, 95% CI 0.53-0.92). Higher etoposide dose levels were associated with subsequent occurrences of AEs (OR 5.97, 95% CI 1.41-30.5) and neutropenia (OR 3.55, 95% CI 1.03-13.3). Dose adjustment did not affect overall survival if the patient completed the 4-dose regimen treatment. With regard to second-line therapy, fewer patients completed 4 treatment cycles, and the most common reason for early discontinuation was tumor progression (n=72, 58%). Male patients (n=118) experienced fewer AEs and better first-line treatment response compared to females (csHR 0.51, 95% CI 0.25-0.90). High-risk patients (defined as ECOG PS 2‐3 or age >75 years) with early discontinuation of therapy had survival outcomes similar to those who did not receive any therapy. Conclusions: Our results indicate that first-line therapies may benefit from more individualized dosing strategies. It would also be beneficial to assess the risk-benefit of treating specific subgroups, including patients receiving second-line therapy. Real-world data proved beneficial for studying therapy response and risk-benefit of treating patient groups that are underrepresented in clinical trials.
- Open Access
- 16 June 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 13, 104538-104554
A Hybrid Approach to Model Hospitals and Evaluate Wards’ Performances
The degree of connectivity among hospital wards and the dynamic nonlinear flow of the patient cause the bottlenecks to begin from non-priority wards, accumulate within the paths, distribute throughout the hospital, and emerge as an overflow in crucial wards. This requires a network-based modeling approach to address the bottlenecks caused by second and third-order wards and significantly influence the overall and emergent performance of multiple wards. Understanding the relative merits of different network modeling and analysis approaches in this complex environment is often challenging and demands a holistic strategy to identify the persistent bottlenecks and provide evidence-based scenarios. This article introduces a novel hybrid modeling approach that integrates network analysis algorithms and agent-based network simulation of patients’ flow over a complete hospital network. Through network analysis, such as structural hole and flow algorithms, the approach identifies the common persistent bottlenecks from the flow and structural perspectives, and percolation and perturbation analyses measure performance improvement of the wards based on the variations in patients’ flows, and the simulations enable the investigation of scenarios. The results indicate the wards and the patient types that can significantly contribute to improving the hospital’s performance. The proposed approach facilitates the holistic dynamic modeling of hospitals, irrespective of their network scale, and enables the identification of bottleneck sources and their associated paths, contributing to a comprehensive assessment of the system’s performance.
- 16 June 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 13, 104538-104554
Open AccessA Hybrid Approach to Model Hospitals and Evaluate Wards’ Performances
The degree of connectivity among hospital wards and the dynamic nonlinear flow of the patient cause the bottlenecks to begin from non-priority wards, accumulate within the paths, distribute throughout the hospital, and emerge as an overflow in crucial wards. This requires a network-based modeling approach to address the bottlenecks caused by second and third-order wards and significantly influence the overall and emergent performance of multiple wards. Understanding the relative merits of different network modeling and analysis approaches in this complex environment is often challenging and demands a holistic strategy to identify the persistent bottlenecks and provide evidence-based scenarios. This article introduces a novel hybrid modeling approach that integrates network analysis algorithms and agent-based network simulation of patients’ flow over a complete hospital network. Through network analysis, such as structural hole and flow algorithms, the approach identifies the common persistent bottlenecks from the flow and structural perspectives, and percolation and perturbation analyses measure performance improvement of the wards based on the variations in patients’ flows, and the simulations enable the investigation of scenarios. The results indicate the wards and the patient types that can significantly contribute to improving the hospital’s performance. The proposed approach facilitates the holistic dynamic modeling of hospitals, irrespective of their network scale, and enables the identification of bottleneck sources and their associated paths, contributing to a comprehensive assessment of the system’s performance.
- Open Access
Real-World Evidence on Dose-Reduction and Treatment Outcomes in Small Cell Lung Cancer; A Bayesian mixed effects and Competitive Risk Approach
Background: Small cell lung cancer (SCLC) is a challenging disease to treat due to rapid progression, development of chemo-resistance, and discrepancies in outcomes between real-world data and clinical trials. Previous studies lack comprehensive analyses of intermediate events and the treatment process, such as treatment decisions, progression of disease, and the occurrence of adverse events (AEs) over time. The aim of this study was to apply advanced statistical methods on a longitudinal SCLC data set in order to identify factors of importance for the risk of AEs and for survival. Methods: Information was collected on the treatment pathways of 421 SCLC patients treated at the Karolinska University Hospital between 2016-2022 (Stockholm, Sweden). Analysis focused on the impact of dose-adjustment on adverse events (AEs), including neutropenia, by estimating odds ratios (OR) using Bayesian mixed-effects modelling. Covariate’s effects on ECOG performance status (PS) deterioration and early discontinuation of chemotherapy with cause-specific hazard ratios (csHR) were explored using competitive risk models. This approach was applied to cohorts of patients receiving first line platinum etoposide, and second line platinum etoposide or platinum irinotecan. Results: At the end of the first line treatment, most patients exhibited tumour regression (n=167). Patients with neutropenia had longer overall survival (HR: 0.70 [0.53, 0.92]). Higher etoposide dose levels were associated with subsequent occurrences of AEs (OR: 5.97 [1.41, 30.5]) and neutropenia (OR: 3.55 [1.03, 13.3]). Dose adjustment did not affect overall survival as long as the patient completed the four-dose regimen treatment. For the second-line, fewer patients completed four treatment cycles and the most common reason of early discontinuation was tumour progression (n=72). Male patients experienced fewer AEs and better first line treatment response compared to females (csHR: 0.51 [0.25, 0.90]). High-risk patients (here defined as ECOG PS 2-3, or age over 75 years) with early discontinuation of therapy had survival outcomes similar to those who did not receive therapy. Conclusions: Our results indicate that SCLC therapies may benefit from more individualized dosing strategies. These strategies would aim to balance improved survival with reduced risk of AEs, particularly neutropenia. It would also be beneficial to assess the risk-benefit of treating specific subgroups, including patients receiving second line therapy. Real-world data are crucial for studying therapy response and risk-benefit of treating patient groups that are underrepresented in clinical trials.
Open AccessReal-World Evidence on Dose-Reduction and Treatment Outcomes in Small Cell Lung Cancer; A Bayesian mixed effects and Competitive Risk Approach
Background: Small cell lung cancer (SCLC) is a challenging disease to treat due to rapid progression, development of chemo-resistance, and discrepancies in outcomes between real-world data and clinical trials. Previous studies lack comprehensive analyses of intermediate events and the treatment process, such as treatment decisions, progression of disease, and the occurrence of adverse events (AEs) over time. The aim of this study was to apply advanced statistical methods on a longitudinal SCLC data set in order to identify factors of importance for the risk of AEs and for survival. Methods: Information was collected on the treatment pathways of 421 SCLC patients treated at the Karolinska University Hospital between 2016-2022 (Stockholm, Sweden). Analysis focused on the impact of dose-adjustment on adverse events (AEs), including neutropenia, by estimating odds ratios (OR) using Bayesian mixed-effects modelling. Covariate’s effects on ECOG performance status (PS) deterioration and early discontinuation of chemotherapy with cause-specific hazard ratios (csHR) were explored using competitive risk models. This approach was applied to cohorts of patients receiving first line platinum etoposide, and second line platinum etoposide or platinum irinotecan. Results: At the end of the first line treatment, most patients exhibited tumour regression (n=167). Patients with neutropenia had longer overall survival (HR: 0.70 [0.53, 0.92]). Higher etoposide dose levels were associated with subsequent occurrences of AEs (OR: 5.97 [1.41, 30.5]) and neutropenia (OR: 3.55 [1.03, 13.3]). Dose adjustment did not affect overall survival as long as the patient completed the four-dose regimen treatment. For the second-line, fewer patients completed four treatment cycles and the most common reason of early discontinuation was tumour progression (n=72). Male patients experienced fewer AEs and better first line treatment response compared to females (csHR: 0.51 [0.25, 0.90]). High-risk patients (here defined as ECOG PS 2-3, or age over 75 years) with early discontinuation of therapy had survival outcomes similar to those who did not receive therapy. Conclusions: Our results indicate that SCLC therapies may benefit from more individualized dosing strategies. These strategies would aim to balance improved survival with reduced risk of AEs, particularly neutropenia. It would also be beneficial to assess the risk-benefit of treating specific subgroups, including patients receiving second line therapy. Real-world data are crucial for studying therapy response and risk-benefit of treating patient groups that are underrepresented in clinical trials.
- Open Access
- 22 August 2024
- Published by IOS Press
- Vol. 316, 678-682
Exploring Hospital Overcrowding with an Explainable Time-to-Event Machine Learning Approach
Emergency department (ED) overcrowding is a complex problem that is intricately linked with the operations of other hospital departments. Leveraging ED real-world production data provides a unique opportunity to comprehend this multifaceted problem holistically. This paper introduces a novel approach to analyse healthcare production data, treating the length of stay of patients, and the follow up decision regarding discharge or admission to the hospital as a time-to-event analysis problem. Our methodology employs traditional survival estimators and machine learning models, and Shapley additive explanations values to interpret the model outcomes. The most relevant features influencing length of stay were whether the patient received a scan at the ED, emergency room urgent visit, age, triage level, and the medical alarm unit category. The clinical insights derived from the explanation of the models holds promise for increase understanding of the overcrowding from the data. Our work demonstrates that a time-to-event approach to the over- crowding serves as a valuable initial to uncover crucial insights for further investigation and policy design.
- 22 August 2024
- Published by IOS Press
- Vol. 316, 678-682
Open AccessExploring Hospital Overcrowding with an Explainable Time-to-Event Machine Learning Approach
Emergency department (ED) overcrowding is a complex problem that is intricately linked with the operations of other hospital departments. Leveraging ED real-world production data provides a unique opportunity to comprehend this multifaceted problem holistically. This paper introduces a novel approach to analyse healthcare production data, treating the length of stay of patients, and the follow up decision regarding discharge or admission to the hospital as a time-to-event analysis problem. Our methodology employs traditional survival estimators and machine learning models, and Shapley additive explanations values to interpret the model outcomes. The most relevant features influencing length of stay were whether the patient received a scan at the ED, emergency room urgent visit, age, triage level, and the medical alarm unit category. The clinical insights derived from the explanation of the models holds promise for increase understanding of the overcrowding from the data. Our work demonstrates that a time-to-event approach to the over- crowding serves as a valuable initial to uncover crucial insights for further investigation and policy design.
- Open Access
- 7 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (8) , e13909
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
The potential of real‐world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach relies on reproducing control arm outcomes by matching real‐world patient cohorts to clinical trial baseline populations. However, recent studies pointed out that there is a lack of replicability, generalisability, and consensus. In this article, we propose a novel approach that aims to explore and examine these discrepancies by concomitantly investigating the impact of selection criteria and operations on the measurements of outcomes from the patient data. We tested the approach on a dataset consisting of small‐cell lung cancer patients receiving platinum‐based chemotherapy regimens from a real‐world data cohort (n = 223) and six clinical trial control arms (n = 1224). The results showed that the discrepancy between real‐world and clinical trial data potentially depends on differences in both patient populations and operational conditions (e.g., frequency of assessments, and censoring), for which further investigation is required. Discovering and accounting for confounders, including hidden effects of differences in operations related to the treatment process and clinical trial study protocol, would potentially allow for improved translation between clinical trials and real‐world data. Continued development of the method presented here to systematically explore and account for these differences could pave the way for transferring learning across clinical studies and developing mutual translation between the real‐world and clinical trials to inform clinical study design.
- 7 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (8) , e13909
Open AccessExploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
The potential of real‐world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach relies on reproducing control arm outcomes by matching real‐world patient cohorts to clinical trial baseline populations. However, recent studies pointed out that there is a lack of replicability, generalisability, and consensus. In this article, we propose a novel approach that aims to explore and examine these discrepancies by concomitantly investigating the impact of selection criteria and operations on the measurements of outcomes from the patient data. We tested the approach on a dataset consisting of small‐cell lung cancer patients receiving platinum‐based chemotherapy regimens from a real‐world data cohort (n = 223) and six clinical trial control arms (n = 1224). The results showed that the discrepancy between real‐world and clinical trial data potentially depends on differences in both patient populations and operational conditions (e.g., frequency of assessments, and censoring), for which further investigation is required. Discovering and accounting for confounders, including hidden effects of differences in operations related to the treatment process and clinical trial study protocol, would potentially allow for improved translation between clinical trials and real‐world data. Continued development of the method presented here to systematically explore and account for these differences could pave the way for transferring learning across clinical studies and developing mutual translation between the real‐world and clinical trials to inform clinical study design.
- Open Access
- 30 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Diagnosing an overcrowded emergency department from its Electronic Health Records
Emergency department overcrowding is a complex problem that persists globally. Data of visits constitute an opportunity to understand its dynamics. However, the gap between the collected information and the real-life clinical processes, and the lack of a whole-system perspective, still constitute a relevant limitation. An analytical pipeline was developed to analyse one-year of production data following the patients that came from the ED (n = 49,938) at Uppsala University Hospital (Uppsala, Sweden) by involving clinical experts in all the steps of the analysis. The key internal issues to the ED were the high volume of generic or non-specific diagnoses from non-urgent visits, and the delayed decision regarding hospital admission caused by several imaging assessments and lack of hospital beds. Furthermore, the external pressure of high frequent re-visits of geriatric, psychiatric, and patients with unspecified diagnoses dramatically contributed to the overcrowding. Our work demonstrates that through analysis of production data of the ED patient flow and participation of clinical experts in the pipeline, it was possible to identify systemic issues and directions for solutions. A critical factor was to take a whole systems perspective, as it opened the scope to the boundary effects of inflow and outflow in the whole healthcare system.
- 30 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessDiagnosing an overcrowded emergency department from its Electronic Health Records
Emergency department overcrowding is a complex problem that persists globally. Data of visits constitute an opportunity to understand its dynamics. However, the gap between the collected information and the real-life clinical processes, and the lack of a whole-system perspective, still constitute a relevant limitation. An analytical pipeline was developed to analyse one-year of production data following the patients that came from the ED (n = 49,938) at Uppsala University Hospital (Uppsala, Sweden) by involving clinical experts in all the steps of the analysis. The key internal issues to the ED were the high volume of generic or non-specific diagnoses from non-urgent visits, and the delayed decision regarding hospital admission caused by several imaging assessments and lack of hospital beds. Furthermore, the external pressure of high frequent re-visits of geriatric, psychiatric, and patients with unspecified diagnoses dramatically contributed to the overcrowding. Our work demonstrates that through analysis of production data of the ED patient flow and participation of clinical experts in the pipeline, it was possible to identify systemic issues and directions for solutions. A critical factor was to take a whole systems perspective, as it opened the scope to the boundary effects of inflow and outflow in the whole healthcare system.
- Open Access
Exploring the discrepancies between clinical trials and real-world data by accounting for Selection criteria, Operations, and Measurements of Outcome
The potential of real-world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach relies on matching real-world patient cohorts to clinical trial baseline covariates using propensity score techniques. However, recent studies pointed out that there is a lack of replicability, generalisability, and consensus. Further, few studies consider differences in operational processes. Systematically accounting for confounders, including hidden effects related to the clinical treatment process and clinical trial study protocol, would potentially allow for improved translation between clinical trial and real-world data and enable learning across translational activities. In this paper, we propose an approach that aims to explore and examine these confounders by investigating the impact of selection criteria and operations on the measurements of outcome. We tested the approach on small cell lung cancer patients receiving platinum-based chemotherapy regimens (n=1,224). The results showed that the discrepancy between real-world and clinical trial data potentially depends on differences in covariate characteristics and operations (e.g., censoring mechanism, the process of pre-trial patient selection related to ECOG-performance status 2 patients). This work builds on current approaches and suggests areas of improvement for systematically accounting for differences in outcomes between study cohorts. Continued development of the method presented here could pave the way for transferring learning across studies and developing mutual translation between the real-world and clinical trials to inform future studies design.
Open AccessExploring the discrepancies between clinical trials and real-world data by accounting for Selection criteria, Operations, and Measurements of Outcome
The potential of real-world data to inform clinical trial design and supplement control arms has gained much interest in recent years. The most common approach relies on matching real-world patient cohorts to clinical trial baseline covariates using propensity score techniques. However, recent studies pointed out that there is a lack of replicability, generalisability, and consensus. Further, few studies consider differences in operational processes. Systematically accounting for confounders, including hidden effects related to the clinical treatment process and clinical trial study protocol, would potentially allow for improved translation between clinical trial and real-world data and enable learning across translational activities. In this paper, we propose an approach that aims to explore and examine these confounders by investigating the impact of selection criteria and operations on the measurements of outcome. We tested the approach on small cell lung cancer patients receiving platinum-based chemotherapy regimens (n=1,224). The results showed that the discrepancy between real-world and clinical trial data potentially depends on differences in covariate characteristics and operations (e.g., censoring mechanism, the process of pre-trial patient selection related to ECOG-performance status 2 patients). This work builds on current approaches and suggests areas of improvement for systematically accounting for differences in outcomes between study cohorts. Continued development of the method presented here could pave the way for transferring learning across studies and developing mutual translation between the real-world and clinical trials to inform future studies design.
- Open Access
- 23 November 2023
- Published by Springer Nature in Research Square
How to diagnose an overcrowded emergency department from its EHRs? Enhancing opportunities and challenges of real-world data from a whole-system perspective
Emergency department overcrowding is a complex problem that persists globally. Data of visits constitute an opportunity to understand it. However, the gap between the collected information and the real-life clinical processes, and the lack of a whole-system perspective, still constitutes a relevant limitation. An analytical pipeline was developed to analyse one-year of production data following the patients that came from the ED (n = 49,938) at Uppsala University Hospital (Uppsala, Sweden) by involving clinical experts in all the steps of the analysis. The key internal issues to the ED were the high volume of generic or non-specific diagnoses from non-urgent visits, and the delayed decision regarding hospital admission caused by several imaging assessments and lack of hospital beds. Furthermore, the external pressure of high frequent re-visits of geriatric, psychiatric, and patients with unspecified diagnoses dramatically contributed to the overcrowding. Our work demonstrates that through analysis of production data of the ED patient flow and participation of clinical experts in the pipeline, it was possible to identify systemic issues and directions for solutions. A critical factor was to take a whole systems perspective, as it opened the scope to the boundary effects of inflow and outflow in the whole healthcare system.
- 23 November 2023
- Published by Springer Nature in Research Square
Open AccessHow to diagnose an overcrowded emergency department from its EHRs? Enhancing opportunities and challenges of real-world data from a whole-system perspective
Emergency department overcrowding is a complex problem that persists globally. Data of visits constitute an opportunity to understand it. However, the gap between the collected information and the real-life clinical processes, and the lack of a whole-system perspective, still constitutes a relevant limitation. An analytical pipeline was developed to analyse one-year of production data following the patients that came from the ED (n = 49,938) at Uppsala University Hospital (Uppsala, Sweden) by involving clinical experts in all the steps of the analysis. The key internal issues to the ED were the high volume of generic or non-specific diagnoses from non-urgent visits, and the delayed decision regarding hospital admission caused by several imaging assessments and lack of hospital beds. Furthermore, the external pressure of high frequent re-visits of geriatric, psychiatric, and patients with unspecified diagnoses dramatically contributed to the overcrowding. Our work demonstrates that through analysis of production data of the ED patient flow and participation of clinical experts in the pipeline, it was possible to identify systemic issues and directions for solutions. A critical factor was to take a whole systems perspective, as it opened the scope to the boundary effects of inflow and outflow in the whole healthcare system.
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S697
EP13.03-14 A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S697
EP13.03-14 A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients
- Open Access
- 18 May 2023
- Published by IOS Press
- Vol. 302, 18-22
Application of Process Mining for Modelling Small Cell Lung Cancer Prognosis
Process mining is a relatively new method that connects data science and process modelling. In the past years a series of applications with health care production data have been presented in process discovery, conformance check and system enhancement. In this paper we apply process mining on clinical oncological data with the purpose of studying survival outcomes and chemotherapy treatment decision in a real-world cohort of small cell lung cancer patients treated at Karolinska University Hospital (Stockholm, Sweden). The results highlighted the potential role of process mining in oncology to study prognosis and survival outcomes with longitudinal models directly extracted from clinical data derived from healthcare.
- 18 May 2023
- Published by IOS Press
- Vol. 302, 18-22
Open AccessApplication of Process Mining for Modelling Small Cell Lung Cancer Prognosis
Process mining is a relatively new method that connects data science and process modelling. In the past years a series of applications with health care production data have been presented in process discovery, conformance check and system enhancement. In this paper we apply process mining on clinical oncological data with the purpose of studying survival outcomes and chemotherapy treatment decision in a real-world cohort of small cell lung cancer patients treated at Karolinska University Hospital (Stockholm, Sweden). The results highlighted the potential role of process mining in oncology to study prognosis and survival outcomes with longitudinal models directly extracted from clinical data derived from healthcare.